DZP

DRUG2 trials

Sponsors

UCB Biopharma SRL

Conditions

Systemic Lupus Erythematosus

Phase 3

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

CompletedNCT04294667

UCB Biopharma SRLSystemic Lupus Erythematosus

Start: 2020-08-12End: 2024-06-04Updated: 2025-05-04

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

RecruitingNCT06617325

UCB Biopharma SRLSystemic Lupus Erythematosus

Start: 2024-11-21End: 2028-05-31Target: 450Updated: 2026-09-04

Related Papers

Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial.

2026-05-29

DAPIROLIZUMAB PEGOL DEMONSTRATED IMPROVEMENT IN QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: LUPUSQOL RESULTS FROM A PHASE 3 TRIAL

The Journal of Rheumatology2025-05-201 citations

IMPROVEMENTS OBSERVED IN SKIN AND JOINT MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH DAPIROLIZUMAB PEGOL TREATMENT: RESULTS FROM A PHASE 3 TRIAL

The Journal of Rheumatology2025-05-20

The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus

Lara D. Veeken2021-12-108 citations